Malignant tumors of the penis are rare, most of them being squamous cell carcinomas (SCCs). We report the case of a 75-year-old man with a large penile mass submitted to partial penectomy. The specimen showed an exophytic mass involving the glans, coronal sulcus, and prepuce.
Tumor budding is defined as a single cell or a cluster of up to 5 tumor cells at the invasion front. Due to the difficulty of identifying patients at high risk for pT1 non-muscle-invasive bladder cancer (NMIBC) and the difficulties in T1 substaging, tumor budding was evaluated as a potential alternative and prognostic parameter in […]
The purpose of this study was to compare the clinical characteristics and the survival of CHEK2 mutation positive and CHEK2 mutation negative patients diagnosed with bladder or kidney cancer. 1016 patients with bladder and 402 cases with kidney cancer and 8302 controls were genotyped for four CHEK2 variants: 1100delC, del5395, IVS2+1G>A and I157T.
(UroToday.com) In the Society of Urologic Oncology (SUO) plenary session held at the American Urological Association (AUA) Virtual Annual Meeting this afternoon, Dr. Quoc-Dien Trinh addressed the question of how the COVID-19 pandemic has affected the diagnosis of urologic cancers.
Zachary Klaassen: Hello, and thank you for joining us for this UroToday discussion of the NCCN Clinical Practice Guidelines in oncology, specifically looking at prostate cancer, which was updated by the NCCN in February 2021. Today, we will be discussing androgen deprivation therapy, and you can see that the NCCN Guidelines have divided androgen deprivation […]
Christopher Wallis: Hello and thank you for joining us for this UroToday discussion of the NCCN Clinical Practice Guidelines in Oncology with a focus on the prostate cancer guidelines from February 2021. This is the third part of our discussion of androgen deprivation therapy. I’m Chris Wallis, an Assistant Professor in the Division of Urology […]
(UroToday.com) Advanced urothelial carcinoma has among the worst prognosis for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance. In the JAVELIN Bladder 100 […]
58 out of 81 (72%) patients achieved a complete response at any time (three or six months), which compares favorably to historical complete response rates of 41% and 18% for FDA-approved therapies pembrolizumab and valrubicin, respectively Median duration of complete response in all responders is 19.9 months and 85% of patients enrolled in the study […]
(UroToday.com) The American Urologic Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Andrei Iagaru discussing the prospective study of 68Ga-RM2 PET/MRI in biochemically recurrent prostate cancer and negative conventional imaging.
(UroToday.com) The American Urologic Association (AUA) annual meeting included a late-breaking abstract session with a presentation by Dr. Laurence Klotz discussing results of the Sentinel® Prostate Cancer Platform, a test for stratification of prostate cancer risk groups. The miR Sentinel® PCC4 Test measures the expressions of 442 small non-coding RNAs extracted from urinary exosomes to differentiate […]
